UBS Group Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $75.00

Gilead Sciences (NASDAQ:GILD) had its price objective cut by investment analysts at UBS Group from $81.00 to $75.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would suggest a potential upside of 12.06% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Oppenheimer decreased their target price on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, February 12th. Cantor Fitzgerald dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $84.71.

Gilead Sciences Price Performance

GILD stock opened at $66.93 on Wednesday. The firm has a market cap of $83.33 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences has a 12-month low of $66.89 and a 12-month high of $87.86. The company’s fifty day simple moving average is $72.25 and its 200 day simple moving average is $76.66.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.67 earnings per share. On average, analysts expect that Gilead Sciences will post 6.55 earnings per share for the current year.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the business. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $25,000. Tompkins Financial Corp grew its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. Private Wealth Management Group LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $29,000. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences in the third quarter valued at $26,000. Finally, Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $29,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.